22.7 USD
-0.26 (-1.13%)
22.52 USD
-0.18 (-0.79%)
Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 525 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPRX is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- In the past year CPRX had a positive cash flow from operations.
- CPRX had positive earnings in each of the past 5 years.
- Each year in the past 5 years CPRX had a positive operating cash flow.
1.2 Ratios
- CPRX has a better Return On Assets (20.69%) than 97.14% of its industry peers.
- The Return On Equity of CPRX (23.65%) is better than 96.76% of its industry peers.
- CPRX has a Return On Invested Capital of 21.23%. This is amongst the best in the industry. CPRX outperforms 97.90% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.07%.
- The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.76% of its industry peers.
- CPRX's Profit Margin has been stable in the last couple of years.
- Looking at the Operating Margin, with a value of 44.78%, CPRX belongs to the top of the industry, outperforming 99.43% of the companies in the same industry.
- CPRX's Operating Margin has improved in the last couple of years.
- The Gross Margin of CPRX (85.68%) is better than 88.38% of its industry peers.
- CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for CPRX has been increased compared to 1 year ago.
- Compared to 5 years ago, CPRX has more shares outstanding
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CPRX has an Altman-Z score of 15.53. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
- CPRX has a Altman-Z score of 15.53. This is amongst the best in the industry. CPRX outperforms 85.90% of its industry peers.
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.53 |
ROIC/WACC2.39
WACC8.88%
2.3 Liquidity
- A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
- CPRX has a better Current ratio (6.62) than 67.62% of its industry peers.
- A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
- The Quick ratio of CPRX (6.40) is better than 66.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 45.76% over the past year.
- Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
- Looking at the last year, CPRX shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
- CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 13.20, CPRX is valued correctly.
- Based on the Price/Earnings ratio, CPRX is valued cheaply inside the industry as 96.95% of the companies are valued more expensively.
- CPRX is valuated cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 12.33, the valuation of CPRX can be described as correct.
- 96.95% of the companies in the same industry are more expensive than CPRX, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, CPRX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 12.33 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 98.48% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.89 | ||
| EV/EBITDA | 7.08 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPRX may justify a higher PE ratio.
- CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.53
PEG (5Y)0.38
EPS Next 2Y18.55%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
22.7
-0.26 (-1.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners86.97%
Inst Owner Change-0.58%
Ins Owners5.48%
Ins Owner Change2.85%
Market Cap2.79B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.12 (54.71%)
Short Float %7.31%
Short Ratio6.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)-0.21%
PT rev (3m)1.26%
EPS NQ rev (1m)7.95%
EPS NQ rev (3m)23.15%
EPS NY rev (1m)1.71%
EPS NY rev (3m)10.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 12.33 | ||
| P/S | 4.83 | ||
| P/FCF | 11.89 | ||
| P/OCF | 11.88 | ||
| P/B | 3.03 | ||
| P/tB | 3.52 | ||
| EV/EBITDA | 7.08 |
EPS(TTM)1.72
EY7.58%
EPS(NY)1.84
Fwd EY8.11%
FCF(TTM)1.91
FCFY8.41%
OCF(TTM)1.91
OCFY8.41%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.53
PEG (5Y)0.38
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.53 |
F-Score6
WACC8.88%
ROIC/WACC2.39
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.37%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 24.97% in the next year.